Novo Nordisk A/S (NYSE:NVO) Shares Purchased by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd boosted its position in shares of Novo Nordisk A/S (NYSE:NVO) by 199.8% in the fourth quarter, HoldingsChannel.com reports. The fund owned 125,081 shares of the company’s stock after purchasing an additional 83,364 shares during the period. Novo Nordisk A/S accounts for 0.7% of Y Intercept Hong Kong Ltd’s holdings, making the stock its 7th largest position. Y Intercept Hong Kong Ltd’s holdings in Novo Nordisk A/S were worth $10,759,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in NVO. Country Club Bank boosted its stake in shares of Novo Nordisk A/S by 11.3% in the 3rd quarter. Country Club Bank now owns 1,837 shares of the company’s stock valued at $222,000 after buying an additional 187 shares during the period. Highland Capital Management LLC acquired a new stake in shares of Novo Nordisk A/S in the 3rd quarter valued at $1,488,000. Allworth Financial LP lifted its holdings in Novo Nordisk A/S by 3.5% during the 3rd quarter. Allworth Financial LP now owns 31,502 shares of the company’s stock worth $3,751,000 after buying an additional 1,062 shares during the last quarter. NorthCrest Asset Manangement LLC lifted its stake in Novo Nordisk A/S by 3.1% during the third quarter. NorthCrest Asset Manangement LLC now owns 11,168 shares of the company’s stock worth $1,330,000 after purchasing an additional 331 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC increased its stake in Novo Nordisk A/S by 14.8% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 289,438 shares of the company’s stock valued at $34,463,000 after purchasing an additional 37,346 shares during the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Up 5.2 %

Shares of NVO opened at $88.07 on Monday. Novo Nordisk A/S has a fifty-two week low of $77.82 and a fifty-two week high of $148.15. The company has a market capitalization of $395.19 billion, a PE ratio of 26.77, a price-to-earnings-growth ratio of 0.90 and a beta of 0.45. The stock has a fifty day moving average of $86.01 and a two-hundred day moving average of $107.99. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.74.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, beating analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. As a group, analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The firm also recently declared a semi-annual dividend, which will be paid on Tuesday, April 8th. Investors of record on Monday, March 31st will be given a dividend of $0.7874 per share. This represents a yield of 1.2%. This is a boost from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. The ex-dividend date is Monday, March 31st. Novo Nordisk A/S’s dividend payout ratio is 21.88%.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the stock. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. BMO Capital Markets lowered their price objective on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research report on Monday, December 23rd. Morgan Stanley assumed coverage on Novo Nordisk A/S in a report on Wednesday, February 12th. They set an “equal weight” rating on the stock. StockNews.com cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Novo Nordisk A/S has a consensus rating of “Moderate Buy” and an average price target of $145.25.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.